ommittee on "Antivirals for Pandemic Influenza: Guidance on Developing a
Distribution and Dispensing Program." Dr. Pavia's research interests include
the epidemiology of influenza and other emerging infections; he has published
more than 100 scientific articles and chapters. He also has significant
experience in the clinical development of antiviral compounds.
Dr. Belshe is the Dianna and J. Joseph Adorjan Endowed Professor of
Infectious Diseases and Immunology; Professor of Medicine, Pediatrics and
Molecular Microbiology, and Director for the Division of Infectious Diseases
and Immunology, at the St. Louis University School of Medicine. He has
published numerous key clinical articles on influenza vaccines and
pathogenesis of influenza.
Dr. Edwards holds the Sarah H. Sell Endowed Professorship in Pediatrics at
Vanderbilt University School of Medicine. She has completed several peer
review publications and published many pivotal articles on infectious disease,
influenza vaccines and pathogenesis, and parainfluenza in pediatric patients.
Dr. Edwards is a current National Institute of Allergy and Infectious Diseases
(NIAID) Advisory Council member and has been awarded multiple grants.
Dr. McGeer is a Professor of Laboratory Medicine and Pathobiology at the
University of Toronto and Director of Infection Control and a Microbiologist
at the Mount Sinai Hospital, Toronto. Dr. McGeer is a practicing clinician
and has served on expert committees including the Council of Canadian
Academies Expert Panel on Influenza and Respiratory Protection, and the
Canadian National Advisory Committee on Immunization.
Dr. Whitley is the Loeb Eminent Scholar Chair in Pediatrics; Professor of
Pediatrics, Microbiology, Medicine and Neurosurgery; Co-Director, University
of Alabama at Birmingham Center for Emerging Infections and Emergency
Preparedness; Director, DivisiPage: 1 2 3 4 Related biology technology :1
. NexBio to Present at 2009 Biotech Showcase2
. Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals3
. NeoStem Completes $11 Million Private Placement Financing to Support Expansion Activities in China, Further Development of NeoStems VSEL Technology and Advancement of Medical Tourism Initiatives4
. Gen-Probe Completes Acquisition of Tepnel Life Sciences5
. Transgenomic Completes Licensing Option With Dana-Farber Cancer Institute on Cold-PCR for Enrichment of DNA Mutations6
. SAFC Biosciences(TM) Completes Conversion of Lenexa Media Milling Facility to Animal Component Free7
. Atritech Completes $30 Million Financing8
. Roche Completes Tender Offer for Genentech9
. Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial10
. China Biologic Products Completes Acquisition of 35% Interest in Xian Huitian Blood Products Co., Ltd.11
. Sangart, Inc. Completes Series F Funding Round